Zydus Lifesciences announced that Usnoflast, a treatment for amyotrophic lateral sclerosis (ALS), has received Orphan Drug Designation from the US FDA. This designation supports the development of ...

Credit: David Herraez Calzada / Shutterstock. The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb trial of its oral NLRP3 ...

Nippon India Small Cap Fund (B) 560.96 28,45,731 0.91 Nippon India Small Cap Fund (IDCW) 560.96 28,45,731 0.91 Nippon India Small Cap Fund (G) 560.96 28,45,731 0.91 ...

What is a hospital-at-home program? A hospital-at-home (HaH) program involves providing hospitalization services, including 24/7 monitoring, in the comfort of the patient’s home rather than a ...

The board approved the demerger of the consumer products division of Cadila Healthcare into Carnation, which is a subsidiary of Cadila Healthcare and the merger of Zydus Hospital and Medical ...

Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited) is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain ...

Zydus Lifesciences Ltd. is a Public Limited Listed company incorporated on 15/05/1995 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is ...

25 Feb, 2010 05 Apr, 2010 1:2 For every 2 share held; Holder will receive 1 bonus shares. 28 Apr, 2006 30 Aug, 2006 1:1 For every 1 share held; Holder will receive 1 bonus shares.

Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 ,inter alia, to consider and approve unaudited financial results for the ...

Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 ,inter alia, to consider and approve unaudited financial results for the ...